Protocol Ledger

NCT07112872 · Phase II · ACTIVE NOT RECRUITING

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

Interventional Phase II clinical trial protocol NCT07112872 sponsored by Roche / Genentech in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-19 Enrollment: 330 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07112872
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)330 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07112872
Protocol FieldVerified Registry Value
NCT IdentifierNCT07112872
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment330 participants (ESTIMATED)
Registered Start Date2025-08-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07112872
Hospital Research SiteLocationSite Profile
Encompass Clinical ResearchSpring Valley, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI